基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 原料药 抗变态反应药 抗组胺药 吡咯咪唑 吡咯咪唑
  • 吡咯咪唑|T1822|TargetMol

吡咯咪唑|T1822|TargetMol

Clemizole
442-52-4
询价 1removed 起订
上海 更新日期:2024-12-12

TargetMol中国(陶术生物)

VIP3年
联系人:邵小姐
手机:4008200310 拨打
邮箱:marketing@tsbiochem.com

产品详情:

中文名称:
吡咯咪唑
英文名称:
Clemizole
CAS号:
442-52-4
品牌:
TargetMol
产地:
美国
保存条件:
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
纯度规格:
98.81%
产品类别:
抑制剂
货号:
T1822

Product Introduction

Bioactivity

名称Clemizole
描述Clemizole is an H1 histamine receptor antagonist, can inhibit NS4B's RNA binding and hepatitis C virus (HCV) replication.
细胞实验Clemizole hydrochloride is dissolved in DMSO and stored, and then diluted with appropriate media before use[1]. Huh7.5 cells are maintained in DMEM supplemented with 1% L-glutamine, 1% penicillin, 1% streptomycin, 1× nonessential amino acids and 10% FBS. Cell lines are passaged twice weekly after treatment with 0.05% trypsin-0.02% EDTA and seeding at a dilution of 1:5. Subconfluent Huh7.5 cells are trypsinized and collected by centrifugation at 700 g for 5 min. The cells are then washed three times in ice-cold RNase-free PBS and resuspended at 1.5×107 cells/mL in PBS. Wild-type or mutant FL-J6/JFH-5′C19Rluc2AUbi RNA for electroporation is generated by transcription of XbaI linearized DNA templates using the T7 MEGAscript kit, followed by purification (RNA transcription and fluorescent labeling). We mixed 5 μg of RNA with 400 μL of washed Huh7.5 cells in a 2-mm-gap cuvette (BTX) and immediately pulsed (0.82 kV, five 99 μs pulses) with a BTX-830 electroporator. After a 10 min recovery at 25°C, pulsed cells are diluted into 10 mL of prewarmed growth medium. Cells from several electroporations are pooled to a common stock and seeded in 6-well plates (5×105 cells per well). After 24 h, medium is replaced and cells are grown in the presence of serial dilutions of the various inhibitory compounds (e.g., Clemizole hydrochloride) identified in the screen. Seventeen commercially available compounds, out of the 18 identified, are analyzed. Untreated cells are used as a negative control for water-soluble compounds. For compounds (e.g., Clemizole hydrochloride) solubilized in DMSO, untreated cells are grown in the presence of corresponding concentrations of the solvent as a negative control. Medium is changed daily. After 72 h of treatment cells are subjected to an Alamar Blue-based viability assay and luciferase assay. After 72 h of treatment cells are incubated for 3 h at 37°C in the presence of 10% Alamar Blue reagent.Plates are then scanned and fluorescence is detected by using FLEXstation II 384. Depending on the inhibitory compound's solvent (e.g., Clemizole hydrochloride), water or DMSO, signal is normalized relatively to untreated samples or samples grown in the presence of DMSO, respectively[1].
体外活性Clemizole hydrochloride 能够抑制 HCV RNA 在细胞培养中的复制,这一作用是通过其对 NS4B RNA 结合活性的抑制实现的,对宿主细胞的毒性很小。Clemizole 对 W55R 突变型 J6/JFH RNA 的半抑制浓度(EC50)约为 18 μM(是野生型 RNA EC50 的 2.25 倍)[1]。Clemizole 是 TRPC5 通道的新型抑制剂,能够在低μM范围内有效阻断 TRPC5 电流和 Ca2+ 入口(IC50=1.0-1.3 μM)。Clemizole 对 TRPC5 的选择性是对其最接近的结构相似体 TRPC4β(IC50=6.4 μM)的六倍,对 TRPC3(IC50=9.1 μM)和 TRPC6(IC50=11.3 μM)的选择性几乎为十倍。作为 TRPC5 的新型阻断剂,Clemizole hydrochloride 的IC50 为 1.1 μM。浓度-反应曲线确认 Clemizole 对 TRPC5 的阻断作用是浓度依赖性的,并显示出明显的 IC50 为 1.1±0.04 μM[2]。
体内活性Clemizole hydrochloride 在 C57BL/6J 小鼠体内的血浆半衰期异常短(测定为0.15小时),并且非常迅速地转化为一种葡萄糖醛酸苷代谢物(M14)和一个脱烷基化代谢物(M12),以及多种较小的代谢物[3]。
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度DMSO : 22.5 mg/mL (69.05 mM), Sonication is recommended.
关键字Histamine Receptor | TRP Channel | Clemizole | inhibit | Hepatitis C virus | Transient receptor potential channels | HCV | Inhibitor | HCV Protease
相关产品Famotidine | Meclizine dihydrochloride | Lidocaine | Alginic acid | Sodium butanoate | Amitriptyline hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride | Artemisinin | EIDD-1931 | Methyl 2-amino-5-bromobenzoate | Ribavirin
相关库抑制剂库 | 抗癌活性化合物库 | 经典已知活性库 | 已知活性化合物库 | 离子通道库 | 抗病毒库 | GPCR靶点分子库 | 免疫/炎症分子化合物库 | 膜蛋白靶向化合物库 | 药物功能重定位化合物库 | 疼痛相关化合物库 | 抗癌临床化合物库
克立咪唑|||吡咯咪唑|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿,致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区,已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库,以及多种类型的生化试剂产品,包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等,此外,我们还建设有CADD(计算机辅助药物设计)研究中心、药理实验室、药化合成平台三大技术中心,全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持,我们将有效帮助您缩短研发周期,取得更成功的结果。

成立日期 (12年)
注册资本 566.265100万人民币
员工人数 100-500人
年营业额 ¥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

吡咯咪唑相关厂家报价 更多

  • 442-52-4
  • 442-52-4
  • 广州优南科技有限公司 VIP
  • 2024-12-06
  • 询价
内容声明
拨打电话 立即询价